← Eichor
Study identifier: NCT06822907 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults

Condition: Acute Febrile Illness · Pneumococcal Infections  ·  Sponsor: Centre Hospitalier Universitaire de Saint Etienne

PhasePhase 4
Planned participants1052
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

Streptococcus pneumoniae is responsible for serious infections associated to numerous hospitalizations and high rate of mortality. The incidence and therefore the burden of pneumococcal infections have been significantly reduced thanks to the use of pneumococcal conjugate vaccines (PCVs). PCVs were shown to be effective against vaccine-type serotypes causing both non-invasive and invasive pneumococcal diseases (IPD) in children and adults. PCVs use in children was shown to have an impact on IPD incidence among adults due to herd immunity and on antimicrobial resistance. To increase the protection of at-risk patients against IPD, the 20-valent PCV (PCV-20) is recently recommended in adults, after a period where PCV-13 followed by pneumococcal polysaccharide vaccine 23 valent (PPV-23) was recommended. PCV-20 effectiveness against IPD and against pneumonia was inferred from immunobridging with PCV-13. Indeed PCV-13 was shown effective to reduce the incidence of low respiratory tract infections and IPD (bacteraemia and meningitis) in 65-years-old-adults and older. Currently immunization against S. pneumoniae is recommended with PCV-20 for adult patients at-risk for IPD such as immunocompromised (=high-risk patients) and in immunocompetent people with underlying chronic conditions (cardiovascular, liver, pulmonary, kidney diseases and diabetes mellitus) (=medium risk patients). However, vaccine coverage against IPD in adults remains low globally, and does not exceed 5 % in France.…

This description comes directly from the study's public registry record.

Talk to the study team

Elisabeth BOTELHO-NEVERS, MD PhD  ·  (0)477829234  ·  Elisabeth.Botelho-Nevers@chu-st-etienne.fr

Always discuss trial participation with your own doctor first.

Locations (24)

CHU de Saint-EtienneSaint-Etienne, France, FranceRecruiting
Centre HospitalierAnnecy, FranceNot Yet Recruiting
Centre Hospitalier UniversitaireBesançon, FranceNot Yet Recruiting
Centre HospitalierBordeaux, FranceNot Yet Recruiting
Centre Hospitalier UniversitaireBrest, FranceNot Yet Recruiting
Centre HospitalierBrest, FranceNot Yet Recruiting
Centre Hospitalier General Metropole SavoieChambéry, FranceNot Yet Recruiting
Centre Hospitalier de CreteilCréteil, FranceNot Yet Recruiting
Centre Hospitalier UniversitaireDijon, FranceNot Yet Recruiting
Centre Hospitalier UniversitaireGrenoble, FranceNot Yet Recruiting
Centre HospitalierLa Roche-sur-Yon, FranceNot Yet Recruiting
Centre Hospitalier GeneralLe Mans, FranceNot Yet Recruiting

+ 12 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06822907